کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10165110 | 1177123 | 2014 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ANPACECNPBNPHFpEFLVEFNYHANT-proBNPHFrEFAngiotensin-converting enzyme - آنژیوتانسین تبدیل آنزیمNew York Heart Association - انجمن قلب نیویورکconfidence interval - فاصله اطمینانHeart failure with preserved ejection fraction - نارسایی قلب با کسر خروجی حفظ شدهheart failure - نارسایی قلبیheart failure with reduced ejection fraction - نارسایی قلبی با کاهش کسر تخلیهhazard ratio - نسبت خطرNeprilysin - نپریلینNatriuretic peptide - پپتید NatriureticC-type natriuretic peptide - پپتید سدیم نوعی پتاسیمatrial natriuretic peptide - پپتید نایروئیدوری دهلیزleft ventricular ejection fraction - کسر خروجی بطن چپ
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Neprilysin is an enzyme that contributes to the breakdown of the biologically active natriuretic peptides and several other vasoactive compounds. Inhibiting neprilysin has been a therapeutic target for several compounds that have been tested in cardiovascular disease, including ecadotril, candoxatril, omapatrilat, and LCZ696. Although ecadotril, candoxatril, and omapatrilat were initially tested in hypertension and/or heart failure, lack of efficacy and side effects led to discontinuation of their development. LCZ696 (sacubitril valsartan) is a first-in-class angiotensin receptor neprilysin inhibitor that has been developed for use in heart failure. This compound is composed of 2 molecular moieties in a single crystalline complex-the angiotensin receptor blocker valsartan and a neprilysin inhibitor prodrug-and has now been tested in hypertension, in a phase 2 trial in heart failure with preserved ejection fraction, and has demonstrated greater efficacy than enalapril in a phase 3 trial in heart failure with reduced ejection fraction. Its ability to inhibit the renin-angiotensin-aldosterone axis and augment the endogenous natriuretic peptide system provides a distinctive mechanism of action in cardiovascular disease.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: JACC: Heart Failure - Volume 2, Issue 6, December 2014, Pages 663-670
Journal: JACC: Heart Failure - Volume 2, Issue 6, December 2014, Pages 663-670
نویسندگان
Orly PharmD, MS, Ryan BS, Scott D. MD,